AcelRx pain treatment meets late-stage study goal
(Reuters) - AcelRx Pharmaceuticals Inc said its experimental drug-device combination for post-operative pain met the main goal of a late-stage study on patients who have undergone major open abdominal surgery.
AcelRx shares jumped 10 percent to $5.49 after the bell on Monday.
The top-line results reported from a 178-patient study of AcelRx's sublingual Sufentanil NanoTab PCA system showed that the patient-controlled drug-device combination helped reduce pain significantly compared with a placebo, the company said.
(Reporting by Zeba Siddiqui in Bangalore; Editing by Roshni Menon)
- U.S. pledges 3,000 troops to fight Ebola; experts say more needed
- Tesla prevails in top Massachusetts court over direct sales
- Russia needs government investment to avoid recession, says former finance minister
- Ukraine ratifies EU deal, offers special status to rebels
- Ahead of independence vote, Britain pledges state funding to Scotland |
Major U.S. poultry firms are administering antibiotics to their flocks far more pervasively than regulators realize, posing a potential risk to human health. Full Article